Comparison
The approved GLP-1 anchor and the investigational amylin analog that Novo pairs with it.
Semaglutide is the approved reference with years of label data; cagrilintide is a complementary satiety-pathway candidate whose real story is the CagriSema combination.
A different receptor system. Semaglutide works through GLP-1; cagrilintide is an amylin analog acting on area-postrema amylin receptors, a parallel satiety pathway that also slows gastric emptying. The hypothesis is additive weight loss from two complementary mechanisms.
Semaglutide, by an enormous margin: multiple approved products with full trial programs. Cagrilintide's standalone human evidence is a 706-person phase 2 weight-management trial plus earlier combination work. It is investigational everywhere.
The phase 3 program is genuinely large and the NDA was filed in December 2025, but REDEFINE 4 missed noninferiority against tirzepatide, so the 'next king' framing is unsupported. Community two-vial imitations of the combination are not the fixed-ratio trial drug.
| Dimension | Semaglutide | Cagrilintide |
|---|---|---|
| Overall evidence grade | A | B |
| Evidence label | Strong human evidence | Moderate human evidence |
| Regulatory status | Approved for specific use | Investigational / not approved |
| Editorial confidence | Moderate confidence | Moderate confidence |
| Efficacy | 5/5 strong | 4/5 substantial |
| Safety | 4/5 substantial | 3/5 emerging |
| Regulatory risk | 1/5 low | 5/5 very high |
| Product quality risk | 1/5 low | 5/5 very high |
| Primary claim categories | Weight management, Type 2 diabetes, FDA-approved product comparison | Weight-management research, Amylin analogue biology, CagriSema comparison limits, FDA compounding limits, Online product-quality risk |
Semaglutide has FDA-approved product labels for specific uses; compounded, salt-form, and online-market claims need separate quality and dosing-risk review.
Cagrilintide is a real clinical-development molecule, not just a peptide-market keyword. Its evidence belongs to investigational amylin-analogue trials, while non-approved products carry separate regulatory and quality risks.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.